{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"AHOD0831","nct_id":"NCT01026220","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ahod0831-nct01026220. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive 2 more courses of ABVE-PC comprising doxorubicin hydrochloride IV over 1-120 minutes and cyclophosphamide IV over 30-60 minutes on days 1 and 2; bleomycin sulfate IV over at least 10 minutes or subcutaneously (SC) and vincristine sulfate IV on days 1 and 8; etoposide IV over 1-2 hours on days 1-3; oral prednisone twice daily on days 1-7; and filgrastim SC or IV daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression.","label":"Regimen I (consolidation therapy)","type":"EXPERIMENTAL"},{"description":"Patients receive ifosfamide IV continuously on days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, and filgrastim SC or IV beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression. Patients then receive 2 more courses of ABVE-PC in the absence of unacceptable toxicity or disease progression.","label":"Regimen II (consolidation therapy)","type":"EXPERIMENTAL"},{"description":"All patients receive ABVE-PC induction therapy then they are assigned to Group 2 (RER), Group 3 (SER) or taken off study if they develop progressive disease.","label":"Induction: all patient","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2022-03-31","type":"ACTUAL"},"conditions":["Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma","Stage III Childhood Hodgkin Lymphoma","Stage IV Childhood Hodgkin Lymphoma"],"enrollment":{"count":166,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"bleomycin sulfate","otherNames":["Blenoxane","BLEO","BLM"],"type":"BIOLOGICAL"},{"name":"doxorubicin hydrochloride","otherNames":["ADM","ADR","Adria","Adriamycin PFS","Adriamycin RDF"],"type":"DRUG"},{"name":"liposomal vincristine sulfate","otherNames":["liposomal vincristine","Marqibo","vincristine liposomal","vincristine sulfate liposome injection"],"type":"DRUG"},{"name":"vinorelbine tartrate","otherNames":["Eunades","navelbine ditartrate","NVB","VNB"],"type":"DRUG"},{"name":"cyclophosphamide","otherNames":["CPM","CTX","Cytoxan","Endoxan","Endoxana"],"type":"DRUG"},{"name":"etoposide phosphate","otherNames":["ETOP","Etopophos"],"type":"DRUG"},{"name":"prednisone","otherNames":["DeCortin","Deltra"],"type":"DRUG"},{"name":"filgrastim","otherNames":["G-CSF","Neupogen"],"type":"BIOLOGICAL"},{"name":"ifosfamide","otherNames":["Cyfos","Holoxan","IFF","IFX","IPP"],"type":"DRUG"}],"last_update":"2022-04-28","lead_sponsor":"Children's Oncology Group","official_title":"A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2012-03-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Second-event-free Survival","timeFrame":"At 4 years from enrollment"},{"measure":"Safety Analysis and Monitoring of Toxic Death","timeFrame":"Within 30 days of protocol treatment at median follow-up of 48 months (range: 1 to 70 months)."}],"references":[{"citation":"Tie X, Shin M, Lee C, Perlman SB, Huemann Z, Weisman AJ, Castellino SM, Kelly KM, McCarten KM, Alazraki AL, Hu J, Cho SY, Bradshaw TJ. Automatic Quantification of Serial PET/CT Images for Pediatric Hodgkin Lymphoma Using a Longitudinally Aware Segmentation Network. Radiol Artif Intell. 2025 May;7(3):e240229. doi: 10.1148/ryai.240229.","pmid":"39969278","type":"DERIVED"},{"citation":"Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28.","pmid":"37505794","type":"DERIVED"}],"start_date":{"date":"2009-12-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma","url":"https://clinicaltrials.gov/study/NCT01026220"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ahod0831-nct01026220"}